Can metoprolol cause diabetes
Pro Research Analysisby 
Searched over 200M research papers
Can Metoprolol Cause Diabetes?
Introduction to Metoprolol and Diabetes Risk
Metoprolol, a beta-blocker commonly prescribed for heart conditions, has been scrutinized for its potential impact on glucose metabolism and the onset of diabetes. This article synthesizes findings from multiple studies to explore whether metoprolol can cause diabetes.
Metoprolol and New Onset Diabetes
Comparative Studies on Metoprolol and Carvedilol
Research from the Carvedilol Or Metoprolol European Trial (COMET) indicates that patients with chronic heart failure treated with metoprolol have a higher incidence of new onset diabetes compared to those treated with carvedilol. Specifically, new onset diabetes was diagnosed in 12.6% of patients on metoprolol versus 10.3% on carvedilol, suggesting a significant difference in diabetes risk between the two medications .
Metabolic Effects of Metoprolol
A study comparing the effects of metoprolol and atenolol on carbohydrate and lipid metabolism found that both drugs caused a decrease in insulin sensitivity and an increase in fasting plasma insulin and blood glucose levels. These metabolic abnormalities are linked to a higher incidence of diabetes in hypertensive patients treated with these beta-blockers .
Metoprolol and Insulin Sensitivity
Insulin-Induced Hypoglycemia
In a study examining the effects of metoprolol on insulin-induced hypoglycemia, it was found that metoprolol potentiated the initial hypoglycemic action of insulin and delayed the return to normal blood glucose levels. This suggests that metoprolol can impair glucose recovery, which is a critical factor in diabetes management .
Long-Term Metabolic Impact
Further research demonstrated that long-term use of metoprolol in hypertensive patients led to decreased glucose uptake mediated by insulin, indicating reduced insulin sensitivity. This reduction in insulin sensitivity is a key factor in the development of diabetes .
Metoprolol in Diabetic Patients
Tolerability and Efficacy in Diabetic Patients
Despite the potential for metoprolol to affect glucose metabolism, studies have shown that it is well-tolerated in diabetic patients with chronic heart failure. The Metoprolol CR/XL Randomized Intervention Trial in Chronic Heart Failure (MERIT-HF) found that metoprolol significantly reduced the risk of hospitalization for heart failure in diabetic patients, indicating its efficacy and safety in this population .
Perioperative Use in Diabetic Patients
The Diabetic Postoperative Mortality and Morbidity (DIPOM) trial evaluated the effects of perioperative metoprolol in diabetic patients undergoing major non-cardiac surgery. The study concluded that metoprolol did not significantly affect mortality and cardiac morbidity, although the confidence intervals were wide, suggesting the need for further research .
Mechanisms of Metoprolol's Impact on Glucose Metabolism
Hepatic Metabolism and Clearance
Research on diabetic rats indicated that metoprolol's hepatic clearance was faster in diabetic conditions, which could influence its overall metabolic effects. This faster clearance might be due to increased hepatic blood flow, although the exact mechanisms remain to be fully understood .
Molecular Mechanisms
At the molecular level, metoprolol has been shown to repress the expression of carnitine palmitoyltransferase-1B (CPT-1B) in diabetic hearts. This repression is mediated by increased binding of upstream stimulatory factor-2 (USF-2) to PPAR-gamma-coactivator 1alpha (PGC1alpha), which in turn decreases PGC1alpha-mediated coactivation of PPAR-alpha and MEF-2A, crucial factors in glucose metabolism .
Conclusion
In summary, evidence suggests that metoprolol can indeed increase the risk of new onset diabetes, particularly when compared to other beta-blockers like carvedilol. This risk is associated with its effects on insulin sensitivity and glucose metabolism. However, metoprolol remains an effective and generally well-tolerated treatment for heart failure in diabetic patients. Further research is needed to fully understand the mechanisms behind its impact on glucose metabolism and to optimize treatment strategies for patients at risk of diabetes.
Sources and full results
Most relevant research papers on this topic
Effects of metoprolol and carvedilol on pre-existing and new onset diabetes in patients with chronic heart failure: data from the Carvedilol Or Metoprolol European Trial (COMET)
New onset diabetes is more likely to occur during metoprolol treatment than carvedilol treatment in patients with chronic heart failure.
Efficacy, safety and tolerability of metoprolol CR/XL in patients with diabetes and chronic heart failure: experiences from MERIT-HF.
Metoprolol CR/XL significantly reduces heart failure hospitalizations and provides a survival benefit, regardless of diabetic status.
Faster non-renal clearance of metoprolol in streptozotocin-induced diabetes mellitus rats.
Metoprolol has a faster non-renal clearance in streptozotocin-induced diabetes mellitus rats, potentially reflecting similar changes in patients with diabetes.
DOI